Abstract
Background
This study investigated the use of gamma-knife-based stereotactic radiosurgery (GKRS) for medium- and large-sized posterior uveal melanoma treatment.
Methods
We assessed 50 eyes from 50 consecutive patients with uveal melanoma who were treated with GKRS. All tumors met the criteria for medium- and large-sized uveal melanomas. Patients underwent a single session treatment under local anesthesia; the prescribed radiation dose at the tumor periphery was standardized to 30 Gy at the 50 % isodose field for all patients. The main outcomes were local tumor control, eye retention, and survival rates.
Results
The median follow-up time was 40 months (16–78 months). The baseline mean tumor diameter was 10.3 mm (7.1–15.7 mm) and the apical tumor height was 8.7 mm (4.1–16.8 mm). After treatment, the mean tumor diameter was 8.7 mm (5.5–12.0 mm) and the tumor height was 6.2 mm (0.5–11.2 mm). Changes in both tumor height and diameter were statistically significant (p < 0.001). The tumor control rate was 90 %, and the eye retention rate was 82 %. A total of nine patients (18 %) developed metastasis, and seven (14 %) died due to metastasis during follow-up. Cataracts (34 %) and radiation maculopathy (30 %) were the most frequent complications, and 14 % of patients developed neovascular glaucoma. Visual acuity (VA) decreased significantly after treatment (p < 0.0001).
Conclusion
Treatment using low doses of GKRS, (30 Gy) is an eye-sparing outpatient option for patients with medium- or large-sized posterior uveal melanomas who are not eligible for brachytherapy or particle therapy. Complications, particularly impaired VA, should be taken into consideration.
Similar content being viewed by others
References
Shields CL, Cater J, Shields JA, Chao A, Krema H, Materin M, Brady LW (2002) Combined plaque radiotherapy and transpupillary thermotherapy for choroidal melanoma: tumor control and treatment complications in 270 consecutive patients. Arch Ophthalmol 120:933–940
Win PH, Robertson DM, Buettner H, McCannel CA, Bennett SR (2006) Extended follow-up of small melanocytic choroidal tumors treated with transpupillary thermotherapy. Arch Ophthalmol 124:503–506
Puusaari I, Damato B, Kivelä T (2007) Transscleral local resection versus iodine brachytherapy for uveal melanomas that are large because of tumor height. Graefes Arch Clin Exp Ophthalmol 245:522–533
Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P (2009) Gamma knife radiosurgeryfor uveal melanoma: 12 years of experience. Br J Ophthalmol 93:40–44
Mueller AJ, Talies S, Schaller UC, Horstmann G, Wowra B, Kampik A (2000) Stereotactic radiosurgery of large uveal melanomas with the gamma-knife. Ophthalmology 107:1381–1387
Dinca EB, Yianni J, Rowe J, Radatz MW, Preotiuc-Pietro D, Rundle P, Rennie I, Kemeny AA (2012) Survival and complications following Gamma Knife radiosurgery or enucleation for ocular melanoma: a 20-year experience. Acta Neurochir (Wien) 154:605–610
Simonova G, Novotny J Jr, Liscak R, Pilbauer J (2002) Leksell gamma knife treatment of uveal melanoma. J Neurosurg 97:635–639
Fakiris AJ, Lo SS, Henderson MA, Witt TC, Worth RM, Danis RP, Des Rosiers PM, Timmerman RD (2007) Gamma-knife-based stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg 85:106–112
Collaborative Ocular Melanoma Study Group (2006) The COMS randomized trial of iodine125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 124:1684–1693
Suh JH (2010) Stereotactic radiosurgery for the management of brain metastases. N Engl J Med 362:1119–1127
Rand RW, Khonsary A, Brown WJ, Winter J, Snow HD (1987) Leksell stereotactic radiosurgery in the treatment of eye melanoma. Neurol Res 9:142–146
Zambrano AD, Chinela AB, Bunge HJ (1989) Stereotactic radiosurgery for uveal melanomas. Protocol for treatment. Archivos Ophthalmol Buenos Aires 64:49–54
Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM (2002) Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 120:1665–1671
Macdonald EC, Cauchi P, Kemp EG (2011) Proton beam therapy for the treatment of uveal melanoma in Scotland. Br J Ophthalmol 95:1691–1695
Quivey JM, Augsburger J, Snelling L, Brady LW (1996) I-125 plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control. Cancer 77:2356–2362
Shields CL, Shields JA, Karlsson U, Menduke H, Brady LW (1990) Enucleation after plaque radiotherapy for posterior uveal melanoma. Histopathologic findings. Ophthalmology 97:1665–1670
Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J (2002) Plaque radiotherapy for large posterior uveal melanomas (> or =8-mm thick) in 354 consecutive patients. Ophthalmology 109:1838–1849
Packer S, Stoller S, Lesser ML, Mandel FS, Finger PT (1992) Long-term results of iodine 125 irradiation of uveal melanoma. Ophthalmology 99:767–773
Lumbroso L, Levy C, Plancher C, Frau E, D’hermies F, Schlienger P, Dendale R, Mammar H, Delacroix S, Nauraye C, Noel G, Ferrand R, Desblancs C, Mazal A, Validire P, Asselain B, Desjardins L (2002) Results of proton beam irradiation for treatment of choroidal melanoma. J Fr Ophtalmol 25:290–297
Char DH, Castro JR, Kroll SM, Irvine AR, Quivey JM, Stone RD (1990) Five-year follow-up of helium ion therapy for uveal melanoma. Arch Ophthalmol 108:209–214
Finger PT, Chin KJ, Duvall G (2009) Palladium-103 for Choroidal Melanoma Study Group. Palladium-103 ophthalmic plaque radiation therapy for choroidal melanoma: 400 treated patients. Ophthalmology 116:790–796
Rouberol F, Roy P, Kodjikian L, Gerard JP, Jean-Louis B, Grange JD (2004) Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol 137:893–900
Sener EC, Kiratli H, Gedik S, Sanac AS (2004) Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma. J AAPOS 8:38–45
Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K, Erickson B (2002) Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. Int J Radiat Oncol Biol Phys 52:989–995
Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM (2005) Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 63:101–108
Fontanesi J, Meyer D, Xu S, Tai D (1993) Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys 26:619–623
Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM (1999) Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 106:1571–1577
Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, Montague P, Moy CS, Schachat AP, Simpson ER, Straatsma BR, Vine AK, Weingeist TA, Collaborative Ocular Melanoma Study Group (2001) Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 108:348–366
Conflict of interest
The authors have no proprietary interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/tWtjDb
The manuscript, or parts of it, have not been and will not be submitted elsewhere for publication.
All coauthors have read the final manuscript within their respective areas of expertise, and participated sufficiently in the study to take responsibility for it and accept its conclusions. Authors have full control of all primary data, and they agree to allow Graefe's Archive for Clinical and Experimental Ophthalmology to review their data upon request.
Rights and permissions
About this article
Cite this article
Sarici, A.M., Pazarli, H. Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol 251, 285–294 (2013). https://doi.org/10.1007/s00417-012-2144-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-012-2144-z